Supriya Lifescience DuPont analysis

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22Mar 2022
5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage
0.74×————
1.04×————
29.7%————
1.12×1.12×1.13×1.17×1.19×
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

SUPRIYA₹869.30

Supriya Lifescience Ltd.

· Pharma & Health
₹ CrorePeersSTARSPARCTHYROCARESHILPAMEDVIYASHRUBICONYATHARTHPARKHOSPS
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY22
31/03/2022
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
Last 12M
30/06/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×————0.74
Interest Burden (Pretax/EBIT) ×————1.04
EBIT Margin %————29.67
Financial Leverage (Assets/Equity) ×1.191.171.131.121.12
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY25 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 89%.